淋巴结状态参与宫颈癌分期合理性的研究进展

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (503 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要宫颈癌是最常见的女性生殖系统恶性肿瘤，既往采用临床分期，2018年国际妇产科联盟首次提出将影像学及病理学诊断的淋巴结转移设立为ⅢC期，体现了淋巴结阳性是影响宫颈癌患者预后的独立危险因素。与此同时，淋巴结转移个数、局部肿瘤大小及宫旁浸润程度也是影响预后的重要决定因素。影像学可通过彩色多普勒超声、CT、MRI、PET/CT等诊断淋巴结转移。经行淋巴结切除术或联合腹主动脉旁淋巴结切除术，局部晚期患者亦可行腹膜后淋巴结切除术后行病理学诊断淋巴结转移。被证实存在淋巴结转移患者的治疗方式建议首选同步放化疗。本文对淋巴结状态参与宫颈癌分期合理性的相关研究作一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	常虹吴玉梅

关键词 ：宫颈肿瘤, 国际妇产科联盟, 分期系统, 淋巴结转移

Abstract：Cervical cancer is the most common malignant tumor of the female reproductive system. In the past, clinical staging was used, in 2018, the International Federation of Obstetrics and Gynecology first proposed to set the lymph node metastasis diagnosed by imaging and pathology as stage ⅢC, reflecting that lymph node positivity was independent risk factors for prognosis of patients with cervical cancer. At the same time, the number of lymph node metastases, the size of the local tumor and the degree of parametrial invasion are also important determinants of prognosis. Imaging can diagnose lymph node metastasis by color doppler ultrasound, CT, MRI, PET/CT, etc. After lymphadenectomy whether or not combine abdominal aortic lymphadenectomy, patients with locally advanced disease can also undergo pathological diagnosis of lymph node metastasis after retroperitoneal lymphadenectomy. Concurrent chemoradiotherapy is recommended for the treatment of patients with confirmed lymph node metastasis. This article reviews the studies on the involvement of lymph node status in the staging of cervical cancer.

Key words： Cervical cancer International Federation of Gynecology and Obstetrics Staging system Lymph nodes metastasis

引用本文:

常虹吴玉梅. 淋巴结状态参与宫颈癌分期合理性的研究进展[J]. 中国医药导报, 2022, 19(22): 54-57.
CHANG Hong WU Yumei. Research progress on rationality of lymph node status involved in cervical cancer staging system. 中国医药导报, 2022, 19(22): 54-57.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I22/54

[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Arbyn M，Weiderpass E，Bruni L，et al. Estimates of Incidence and Mortality of Cervical Cancer in 2018：a worldwide analysis [J]. Lancet Glob Health，2020，8（2）：e191-e203.
[3] Salvo G，Odetto D，Pareja R，et al. Revised 2018 International Federation of Gynecology and Obstetrics（FIGO） cervical cancer staging：A review of gaps and questions that remain [J]. Int J Gynecol Cancer，2020，30（6）：873-878.
[4] Bhatla N，Aoki D，Sharma DN，et al. Cancer of the cervix uteri [J]. Int J Gynaecol Obstet，2018，2：22-36.
[5] Chen Y，Fang C，Zhang K，et al. Distribution patterns of lymph node metastasis in early stage invasive cervical cancer [J]. Medicine （Baltimore），2020，99（42）：e22285.
[6] Zigras T，Lennox G，Willows K，et al. Early Cervical Cancer：Current Dilemmas of Staging and Surgery [J]. Curr Oncol Rep，2017，19（8）：51.
[7] Huang BX，Fang F. Progress in the Study of Lymph Node Metastasis in Early-stage Cervical Cancer [J]. Curr Med Sci，2018 ，38（4）：567-574.
[8] Gien LT，Covens A. Lymph node assessment in cervical cancer：prognostic and therapeutic implications [J]. J Surg Oncol，2009，99（4）：242-247.
[9] Cohen PA，Jhingran A，Oaknin A，et al. Cervical cancer [J]. Lancet，2019，393（10167）：169-182.
[10] Liu X，Wang J，Hu K，et al. Validation of the 2018 FIGO Staging System of Cervical Cancer for Stage Ⅲ Patients with a Cohort from China [J]. Cancer Manag Res，2020， 12：1405-1410.
[11] Matsuo K，Machida H，Mandelbaum RS，et al. Validation of the 2018 FIGO cervical cancer staging system [J]. Gynecol Oncol，2019，152（1）：87-93.
[12] Grigsby PW，Massad LS，Mutch DG，et al. FIGO 2018 staging criteria for cervical cancer：Impact on stage migration and survival [J]. Gynecol Oncol，2020，157（3）：639-643.
[13] Wright JD，Matsuo K，Huang Y，et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines [J]. Obstet Gynecol，2019，134（1）：49-57.
[14] Pedone Anchora L，Carbone V，Gallotta V，et al. Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 FIGO Staging Classification of Early Stage Cervical Cancer? [J]. Cancers （Basel），2020，12（6）：1552.
[15] Aslan K，Meydanli MM，Oz M，et al. The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy [J]. J Gynecol Oncol，2020，31（1）：e1.
[16] 周晖，刘昀昀，罗铭，等.《2022 NCCN子宫颈癌临床实践指南（第1版）》解读[J].中国实用妇科与产科杂志，2021，37（12）：1220-1226.
[17] Devine C，Viswanathan C，Faria S，et al. Imaging and Staging of Cervical Cancer [J]. Semin Ultrasound CT MR，2019，40（4）：280-286.
[18] Lee SI，Atri M. 2018 FIGO Staging System for Uterine Cervical Cancer：Enter Cross-sectional Imaging [J]. Radiology，2019，292（1）：15-24.
[19] Liu B，Gao S，Li S. A Comprehensive Comparison of CT，MRI，Positron Emission Tomography or Positron Emission Tomography/CT，and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer：A Meta-Analysis Based on 67 Studies [J]. Gynecol Obstet Invest，2017，82（3）：209-222．
[20] 洪士彬，程杰军，狄文.MRI在宫颈癌分期评估中的临床应用及研究进展[J].国际妇产科学杂志，2021，48（6）：634-638.
[21] Saleh M，Virarkar M，Javadi S，et al. Cervical Cancer：2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging [J]. AJR Am J Roentgenol，2020，214（5）：1182-1195.
[22] Bourgioti C，Chatoupis K，Rodolakis A，et al. Incremental prognostic value of MRI in the staging of early cervical cancer：a prospective study and review of the literature [J]. Clin Imaging，2016，40（1）：72-78.
[23] Luo L，Luo Q，Tang L. Diagnostic value and clinical significance of MRI and CT in detecting lymph node metastasis of early cervical cancer [J]. Oncol Lett，2020，19（1）：700-706.
[24] 李小燕，孙洪赞，卢再鸣.宫颈癌宫旁浸润影像诊断研究进展[J].现代肿瘤医学，2020，28（9）：1571-1574.
[25] Ruan J，Zhang Y，Ren H. Meta-analysis of PET/CT Detect Lymph Nodes Metastases of Cervical Cancer [J]. Open Med （Wars），2018，13：436-442.
[26] 刘萍，黎志强，柳攀，等.FIGO2018子宫颈癌分期Ⅲ期各亚期设置合理性探讨[J].中国实用妇科与产科杂志，2021，37（6）：669-672.
[27] Gold MA，Tian C，Whitney CW，et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma：a Gynecologic Oncology Group Study [J]. Cancer，2008，112（9）：1954-1963.
[28] Gonzalez-Benitez C，Salas P，Grabowski JP，et al. Lack of survival benefit of para-aortic lymphadenectomy in advanced cervical cancer [J]. Gynecol Obstet Invest，2019， 84（4）：407-411.
[29] Delara R，Yang J，Buckner-Petty S，et al. Surgical or imaging lymph node assessment in locally advanced cervical cancer：a systematic review and meta-analysis [J]. J Gynecol Oncol，2020，31（6）：e79.
[30] Charles A，Leath Ⅲ，Monk BJ. Twenty-first Century cervical cancer management：A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years [J]. Gynecol Oncol，2018，150（3）：391-397.